Augurex Life Sciences Corp., a diagnostics company based in Vancouver, British Columbia, has announced that Mayo Clinic Laboratories will now offer 14-3-3eta serum testing, a significant addition to its diagnostic testing portfolio for rheumatoid arthritis (RA). The introduction of this biomarker testing aims to improve the accuracy of RA diagnosis, which is critical for timely treatment and management of the disease.
The 14-3-3eta biomarker is intended to complement other established tests, such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, providing physicians with a broader diagnostic toolkit. This development reflects ongoing advances in understanding autoimmune and inflammatory diseases, and highlights the importance of innovative testing in supporting patient outcomes.
As Mayo Clinic Laboratories implements this new testing option, it is expected to enhance the availability of resources for healthcare providers, aiding in the early diagnosis and intervention strategies for individuals with rheumatoid arthritis. Augurex's focus on autoimmune conditions underlines its commitment to improving diagnostic practices in the medical community.
Analyzed Canadian Outlets (2)
1 headline · wire copies grouped